nach oben

European Journal of Orthopaedic Surgery & Traumatology

Erschienen in:

05.09.2020 | General Review

Silver-coated megaprosthesis in prevention and treatment of peri-prosthetic infections: a systematic review and meta-analysis about efficacy and toxicity in primary and revision surgery

verfasst von: Michele Fiore, Andrea Sambri, Riccardo Zucchini, Claudio Giannini, Davide Maria Donati, Massimiliano De Paolis

Erschienen in: European Journal of Orthopaedic Surgery & Traumatology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Aim

Prosthetic joint infection (PJI) is a common complication following orthopedic megaprosthetic implantations (EPR), estimated up to 50%. Silver coatings were introduced in order to reduce the incidence of PJI, by using the antibacterial activity of silver. Three different silver coatings are available: MUTARS^® (Implantcast), Agluna^® (Accentus Medical), PorAg^® (Waldemar Link). The aim of this review is to provide an overview on efficacy and safety of silver-coated EPR both in primary and revision surgery, comparing infection rate according to the type of implant.

Methods

Through an electronic systematic search, we reviewed the articles concerning silver-coated EPRs. Infection rate, silver-related complications, local and blood concentrations of the silver were evaluated. Meta-analyses were performed to compare results from each study included.

Results

Nineteen studies were included. The overall infection rate in patients with silver-coated implants was 17.6% (133/755). Overall infection rate in primary silver-coated EPR was been 9.2% (44/445), compared to 11.2% (57/507) of non-silver-coated implants. The overall infection rate after revisions was 13.7% (25/183) in patients with silver-coated EPR and 29.2% (47/161) when uncoated EPR were used, revealing a strength statistically significative utility of silver coatings in preventing infections in this group (p: 0.019). Generally, the use of MUTARS^® EPR had produced an almost constant decrease in the incidence of primary PJI but there are few data on the effectiveness in revisions. The results from the use of Agluna^® in both primary and revisions implants are inconstant. Conversely, PorAg^® had proven to be effective both in PJI prevention but, especially, when used in PJI revision settings. Local argyria was reported in 8 out of 357 patients (2.2%), while no systemic complications were described. Local and blood concentrations of silver were always reported very far to the threshold of toxicity, with the lowest concentration found using PorAg^®.

Conclusions

Silver-coated EPRs are safe and effective in reduction in PJI and re-infection rate, in particular when used in higher risk patients and after two-stage revisions to fight PJI.

Izakovicova P, Borens O, Trampuz A (2019) Periprosthetic joint infection: current concepts and outlook. EFORT Open Rev 4(7):482–494PubMedPubMedCentral

Donati F et al (2016) Silver-coated hip megaprosthesis in oncological limb savage surgery. Biomed Res Int 2016:9079041PubMedPubMedCentral

Glehr M et al (2013) Argyria following the use of silver-coated megaprostheses: no association between the development of local argyria and elevated silver levels. Bone Jt J 95-B(7):988–992

Hardes J et al (2007) Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials 28(18):2869–2875PubMed

Hardes J et al (2017) Silver-coated megaprosthesis of the proximal tibia in patients with sarcoma. J Arthroplasty 32(7):2208–2213PubMed

Hardes J et al (2010) Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol 101(5):389–395PubMed

Hussmann B et al (2013) Measurement of the silver ion concentration in wound fluids after implantation of silver-coated megaprostheses: correlation with the clinical outcome. Biomed Res Int 2013:763096PubMedPubMedCentral

Medellin MR et al (2019) Mechanisms of failure and survival of total femoral endoprosthetic replacements. Bone Jt J 101-B(5):522–528

Parry MC et al (2019) Silver-coated (Agluna(R)) tumour prostheses can be a protective factor against infection in high risk failure patients. Eur J Surg Oncol 45(4):704–710PubMed

10.

Sambri A et al (2019) Is arthrodesis a reliable salvage option following two-stage revision for suspected infection in proximal tibial replacements? A multi-institutional study. J Knee Surg 32(9):911–918PubMed

11.

Wilding CP et al (2016) Can a silver-coated arthrodesis implant provide a viable alternative to above knee amputation in the unsalvageable, infected total knee arthroplasty? J Arthroplasty 31(11):2542–2547PubMed

12.

Piccioli A et al (2016) Infective complications in tumour endoprostheses implanted after pathological fracture of the limbs. Injury 47(Suppl 4):S22–S28PubMed

13.

Schmolders J et al (2017) Silver-coated endoprosthetic replacement of the proximal humerus in case of tumour-is there an increased risk of periprosthetic infection by using a trevira tube? Int Orthop 41(2):423–428PubMed

14.

Schmolders J et al (2017) Lower limb reconstruction in tumor patients using modular silver-coated megaprostheses with regard to perimegaprosthetic joint infection: a case series, including 100 patients and review of the literature. Arch Orthop Trauma Surg 137(2):149–153PubMed

15.

Scoccianti G et al (2016) Levels of silver ions in body fluids and clinical results in silver-coated megaprostheses after tumour, trauma or failed arthroplasty. Injury 47(Suppl 4):S11–S16PubMed

16.

Streitbuerger A et al (2019) Silver-coated megaprostheses in the proximal femur in patients with sarcoma. Eur J Orthop Surg Traumatol 29(1):79–85PubMed

17.

Trovarelli G et al (2019) Infection in orthopaedic oncology: crucial problem in modern reconstructive techniques. Eur Rev Med Pharmacol Sci 23(2 Suppl):271–278PubMed

18.

Trovarelli G et al (2019) What is the survival and function of modular reverse total shoulder prostheses in patients undergoing tumor resections in whom an innervated deltoid muscle can be preserved? Clin Orthop Relat Res 477(11):2495–2507PubMedPubMedCentral

19.

Wafa H et al (2015) Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study. Bone Jt J 97-B(2):252–257

20.

Zajonz D et al (2017) Silver-coated modular Megaendoprostheses in salvage revision arthroplasty after periimplant infection with extensive bone loss—a pilot study of 34 patients. BMC Musculoskelet Disord 18(1):383PubMedPubMedCentral

21.

Jeys LM et al (2005) Periprosthetic infection in patients treated for an orthopaedic oncological condition. J Bone Jt Surg Am 87(4):842–849

22.

Sambri A, Zucchini R, Giannini C et al (2020) Silver-coated (PorAg^®) endoprosthesis can be protective against reinfection in the treatment of tumor prostheses infection. Eur J Orthop Surg Traumatol. https://doi.org/10.1007/s00590-020-02725-zCrossRefPubMed

23.

Jeys L, Grimer R (2009) The long-term risks of infection and amputation with limb salvage surgery using endoprostheses. Recent Results Cancer Res 179:75–84PubMed

24.

Romano CL et al (2015) Antibacterial coating of implants in orthopaedics and trauma: a classification proposal in an evolving panorama. J Orthop Surg Res 10:157PubMedPubMedCentral

25.

Getzlaf MA et al (2016) Multi-disciplinary antimicrobial strategies for improving orthopaedic implants to prevent prosthetic joint infections in hip and knee. J Orthop Res 34(2):177–186PubMed

26.

Kim TN et al (1998) Antimicrobial effects of metal ions (Ag⁺, Cu²⁺, Zn²⁺) in hydroxyapatite. J Mater Sci Mater Med 9(3):129–134PubMed

27.

Chambers CW, Proctor CM, Kabler PW (1962) Bactericidal effect of low concentrations of silver. J AWWA 54(2):208–216

28.

Gosheger G et al (2004) Silver-coated megaendoprostheses in a rabbit model—an analysis of the infection rate and toxicological side effects. Biomaterials 25(24):5547–5556PubMed

29.

Szaraniec B, Goryczka T (2017) Structure and properties of Ti–Ag alloys produced by powder metallurgy. J Alloys Compd 709:464–472

30.

Cao H et al (2011) Biological actions of silver nanoparticles embedded in titanium controlled by micro-galvanic effects. Biomaterials 32(3):693–705PubMed

31.

Feng QL et al (2000) A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 52(4):662–668PubMed

32.

Tweden KS et al (1997) Biocompatibility of silver-modified polyester for antimicrobial protection of prosthetic valves. J Heart Valve Dis 6(5):553–561PubMed

33.

Wan AT et al (1991) Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem 37(10 Pt 1):1683–1687PubMed

34.

Russell AD, Hugo WB (1994) 7 Antimicrobial activity and action of silver. In: Ellis GP, Luscombe DK (eds) Progress in medicinal chemistry. Elsevier, Amsterdam, pp 351–370

35.

Hetrick EM, Schoenfisch MH (2006) Reducing implant-related infections: active release strategies. Chem Soc Rev 35(9):780–789PubMed

36.

Palanisamy NK et al (2014) Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa. J Nanobiotechnol 12:2

37.

Afkhami F et al (2015) Antibiofilm efficacy of silver nanoparticles as a vehicle for calcium hydroxide medicament against Enterococcus faecalis. J Dent 43(12):1573–1579PubMed

38.

Gallo J et al (2016) Silver nanocoating technology in the prevention of prosthetic joint infection. Materials (Basel) 9(5):337

39.

Gupta A et al (2001) Diversity of silver resistance genes in IncH incompatibility group plasmids. Microbiology 147(Pt 12):3393–3402PubMed

40.

Silver S (2003) Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev 27(2–3):341–353PubMed

41.

Shahabadi N, Maghsudi M, Ahmadipour Z (2012) Study on the interaction of silver(I) complex with bovine serum albumin by spectroscopic techniques. Spectrochim Acta A Mol Biomol Spectrosc 92:184–188PubMed

42.

Schierholz JM et al (1998) Efficacy of silver-coated medical devices. J Hosp Infect 40(4):257–262PubMed

43.

Brutel de la Riviere A et al (2000) First clinical experience with a mechanical valve with silver coating. J Heart Valve Dis 9(1):123–129 (discussion 129-30)PubMed

44.

Lansdown AB (2007) Critical observations on the neurotoxicity of silver. Crit Rev Toxicol 37(3):237–250PubMed

45.

Shavlovski MM et al (1995) Embryotoxicity of silver ions is diminished by ceruloplasmin—further evidence for its role in the transport of copper. Biometals 8(2):122–128PubMed

46.

Clement JL, Jarrett PS (1994) Antibacterial silver. Met Based Drugs 1(5–6):467–482PubMedPubMedCentral

47.

Pauksch L et al (2014) Biocompatibility of silver nanoparticles and silver ions in primary human mesenchymal stem cells and osteoblasts. Acta Biomater 10(1):439–449PubMed

48.

Necula BS et al (2012) In vitro cytotoxicity evaluation of porous TiO(2)–Ag antibacterial coatings for human fetal osteoblasts. Acta Biomater 8(11):4191–4197PubMed

49.

Lansdown AB (2010) A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharmacol Sci 2010:910686PubMedPubMedCentral

50.

von Eiff C, Proctor RA, Peters G (2001) Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med 110(4):63-4, 69-70, 73-6

Titel: Silver-coated megaprosthesis in prevention and treatment of peri-prosthetic infections: a systematic review and meta-analysis about efficacy and toxicity in primary and revision surgery
verfasst von: Michele Fiore
Andrea Sambri
Riccardo Zucchini
Claudio Giannini
Davide Maria Donati
Massimiliano De Paolis
Publikationsdatum: 05.09.2020
Verlag: Springer Paris
Erschienen in: European Journal of Orthopaedic Surgery & Traumatology / Ausgabe 2/2021
Print ISSN: 1633-8065
Elektronische ISSN: 1432-1068
DOI: https://doi.org/10.1007/s00590-020-02779-z

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Silver-coated megaprosthesis in prevention and treatment of peri-prosthetic infections: a systematic review and meta-analysis about efficacy and toxicity in primary and revision surgery

Abstract